BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2026 8:43:34 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-07-28 14:35 |
|
Peer-Review Started |
|
2025-08-04 06:33 |
|
First Decision by Editorial Office Director |
|
2025-08-14 09:18 |
|
Return for Revision |
|
2025-08-14 09:18 |
|
Revised |
|
2025-10-12 13:02 |
|
Publication Fee Transferred |
|
2025-10-14 02:15 |
|
Second Decision by Editor |
|
2025-11-18 09:53 |
|
Second Decision by Editor-in-Chief |
|
2025-11-24 10:13 |
|
Final Decision by Editorial Office Director |
|
2025-11-27 04:19 |
|
Articles in Press |
|
2025-11-27 04:19 |
 |
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-26 06:23 |
|
Publish the Manuscript Online |
|
2026-02-06 08:43 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Basic Study |
| Article Title |
Fibroblast growth factor 1 alleviates diabetic nephropathy by reducing renal lipid accumulation in diabetic kidney
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ying-Jian Li, He-Yu Ge, Gui-Gui Zhang, Hao-Yu Chen, Yu-Jia Xi, Kai Wang, Yin-Li Huang, Chi Zhang, Xia Fan and Xiao-Qing Yan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82470453 |
| National Natural Science Foundation of China |
No. 82370832 |
| Natural Science Foundation of Zhejiang Province |
No. LY22H020005 |
| The Summit Advancement Disciplines of Zhejiang Province (Wenzhou Medical University-Pharmaceutics) |
|
|
| Corresponding Author |
Xiao-Qing Yan, Associate Professor, School of Pharmaceutical Sciences, Wenzhou Medical University, University-Town, Wenzhou 325035, Zhejiang Province, China. yanxiaoqing@wmu.edu.cn |
| Key Words |
Fibroblast growth factor 1; Diabetic nephropathy; Lipid accumulation; AMP-activated protein kinase; Human kidney-2; Carnitine palmitoyl transferase 1 alpha |
| Core Tip |
Fibroblast growth factor 1 (FGF1) can effectively ameliorate diabetic nephropathy as reflected by improved renal function and alleviation of kidney morphological abnormalities. FGF1 alleviates renal lipid accumulation, as evidenced by decreased triglyceride content and repressed adipose differentiation-related protein expression, via inhibiting fatty acid uptake and promoting lipid catabolism in diabetic kidney. Mechanical studies demonstrated that FGF1 modulates renal lipid metabolism via restoring AMP-activated protein kinase activity and peroxisome proliferator-activated receptor alpha expression. |
| Publish Date |
2026-02-06 08:43 |
| Citation |
Li YJ, Ge HY, Zhang GG, Chen HY, Xi YJ, Wang K, Huang YL, Zhang C, Fan X, Yan XQ. Fibroblast growth factor 1 alleviates diabetic nephropathy by reducing renal lipid accumulation in diabetic kidney. World J Diabetes 2026; 17(2): 112475 |
| URL |
https://www.wjgnet.com/1948-9358/full/v17/i2/112475.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v17.i2.112475 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
